Geoff Harris Email

Founder and Advisor to Ocelot Bio . Ocelot Bio

Current Roles

Employees:
24
Revenue:
$1.9M
About
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). Ocelot Bio plans to initiate a Phase 2 clinical trial of OCE-205 in the first half of 2022 in HRS-AKI, for which there has been no therapeutic drug innovation in over two decades. The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock Ventures, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
Ocelot Bio Address
12670 High Bluff Dr.
San Diego, CA
Ocelot Bio Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.